Written by: Bryan J. Brinda, PharmD
Download Here

This PQI will discuss proper patient selection and management of adverse events related to the administration of oral gilteritinib pharmacotherapy in patients with relapsed/refractory AML that have an FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test. Optimal patient identification, dosing, and follow-up are essential to help patients benefit fully while taking this medication. Continue reading Gilteritinib (XOSPATA) for Relapsed/Refractory Acute Myeloid Leukemia (AML)

Read More

Written By: Jon Suyko, PharmD, BCPS UCHealth Highlands Ranch
Download Here

Description Venetoclax is as selective inhibitor of B cell lymphoma-2 (BCL-2). Inhibition of BCL-2 by venetoclax results in cytotoxic activity in tumor cells that overexpress BCL-2 by restoring apoptosis. Venetoclax is indicated in Acute myeloid leukemia (AML), chronic lymphoid leukemia (CLL) and small lymphocytic leukemia (SLL) in patients with or without chromosome 17p deletion.  During the ramp-up phase, patients are titrated on venetoclax and assigned a risk category based on tumor burden and potential for developing Tumor Lysis Syndrome (TLS).  These risk stratifications create special challenges for the dispensing of venetoclax.   Some medium-risk and all high-risk patients may require hospital admission during titration; communication between the oncology pharmacist, nurse, lab technicians, hematologist, and the patient will ensure the recommended administration guidelines and lab monitoring are followed to ensure patient safety and best outcomes.

Continue reading Venetoclax Risk Stratification, Dosing, and Dispensing Procedure

Read More

Written by: Danny Olszta, PharmD, BCOP Jolliet Oncology Hematology Associates
Download Here

For patients with Non‐Small Cell Lung Cancer (NSCLC) that have a del 19 EGFR mutation appropriate for first‐line treatment with an epidermal growth factor receptor (EGFR) Inhibitor, Afatinib (Gilotrif) has a clear overall survival (OS) benefit compared to chemotherapy. If another EGFR inhibitor is being prescribed for a patient with a del 19 EGFR mutation, the pharmacist will contact the Physician to determine why the current therapy was chosen.

Continue reading EGFR Inhibitors

Read More

Written by Danny Olszta, PharmD, BCOP Jolliet Oncology Hematology Associates
Download Here

Chronic Lymphocytic Leukemia (CLL) diagnosis with the chromosomal abnormality of 17p Deletion is associated with a poor prognosis. The 17p deletion is found 3‐10% of the time at diagnosis, but 30‐ 50% at relapse. Testing rates at diagnosis and especially relapse are low. Venetoclax is approved in patients who have relapsed after one therapy and have the 17p deletion. Continue reading CLL and Del17P

Read More

Written By: Chris Sellers, RPh Area Manager, Texas Oncology
Download Here

The purpose is to provide management of common adverse events, follow-up with patients and dose modifications. Dose adjustments are common and greatly reduced frequency and severity of adverse reactions.  Continue reading NSCLC Afatinib Management

Read More